ClinicalTrials.gov
public full text
Public Domain
Phase IIa Dose-Expansion and Biomarker Study of OPB-111077
This is a phase IIa open-label, non-randomized dose-expansion study of OPB-111077 in patients with advanced, treatment refractory cancers who have biopsy-amenable lesions at study entry.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Safety and Biomarker of OPB-111077 in Subjects With Advanced Solid Tumor#827700
- PRO1107 in Patients With Advanced Solid Tumors#852344
- Phase I Study of OPB-51602 in Patients With Hematologic Malignancies#1151569
- A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor#1032871
- Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors#300272
Record · ID 1172888
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive